Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2024 Apr 24;9(5):102924. doi: 10.1016/j.esmoop.2024.102924

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2024 The Authors

This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

PMC Copyright notice

Waterfall and spider plots of brain lesion measurements. (A) Best percentage change in sum of diameters of measurable intracranial lesions from baseline in patients with BMs. The red line at 20% indicates PD; the black line at −30% indicates PR. ∗Patients without prior radiation therapy to the brain. Brain lesion measurements over time in (B) the T-DXd subgroup and (C) the T-DM1 subgroup.

BM, brain metastases; EOT, end of treatment; T-DM1, trastuzumab emtansine; T-DXd, trastuzumab deruxtecan; Trt, treatment.

Waterfall and spider plots of brain lesion measurements. (A) Best percentage change in sum of diameters of measurable intracranial lesions from baseline in patients with BMs. The red line at 20% indicates PD; the black line at −30% indicates PR. ∗Patients without prior radiation therapy to the brain. Brain lesion measurements over time in (B) the T-DXd subgroup and (C) the T-DM1 subgroup.

BM, brain metastases; EOT, end of treatment; T-DM1, trastuzumab emtansine; T-DXd, trastuzumab deruxtecan; Trt, treatment.